Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEED-AD: Endocrine Disruption and Alzheimer's in Women
NCT03821857Phase 4Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jun 2019
- Primary completion
- May 2030
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial, sponsored by Mayo Clinic. Primary endpoints: 18F-Flortaucipir PET imaging at 1 day and Pittsburgh compound-B PET imaging at 1 day. Started Jun 2019; status: recruiting.
Beyond the preview
Go deeper on NCT03821857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03821857.